Oragenics, Inc. Participates in the 3rd Nasal Formulation & Delivery Summit
Oragenics (NYSE American: OGEN) announced its participation in the 3rd Nasal Formulation & Delivery Summit held April 1-3, 2025, in Boston. Chief Medical Officer Dr. James Kelly joined a panel discussion, sharing insights on intranasal drug delivery optimization and neurological treatment approaches.
The company is developing ONP-002, a novel neurosteroid designed to treat mild traumatic brain injury (mTBI) or concussion through intranasal administration, which enables rapid absorption and targeted brain delivery. The summit gathered industry leaders to discuss innovations in intranasal drug delivery, focusing on CNS therapeutics, emergency-use treatments, and infectious disease applications.
Oragenics (NYSE American: OGEN) ha annunciato la sua partecipazione al 3° Summit sulla Formulazione e Consegna Nasale, che si terrà dal 1 al 3 aprile 2025 a Boston. Il Chief Medical Officer, Dr. James Kelly, ha partecipato a una discussione di panel, condividendo approfondimenti sull'ottimizzazione della somministrazione intranasale dei farmaci e sugli approcci terapeutici neurologici.
L'azienda sta sviluppando ONP-002, un nuovo neurosteroide progettato per trattare lesioni cerebrali traumatiche lievi (mTBI) o commozioni cerebrali attraverso somministrazione intranasale, che consente un assorbimento rapido e una consegna mirata al cervello. Il summit ha riunito leader del settore per discutere le innovazioni nella somministrazione intranasale dei farmaci, con un focus sui terapeutici del SNC, trattamenti per uso d'emergenza e applicazioni per malattie infettive.
Oragenics (NYSE American: OGEN) anunció su participación en el 3er Summit de Formulación y Entrega Nasal, que se llevará a cabo del 1 al 3 de abril de 2025 en Boston. El Director Médico, Dr. James Kelly, se unió a una discusión en panel, compartiendo ideas sobre la optimización de la entrega intranasal de medicamentos y enfoques de tratamiento neurológico.
La empresa está desarrollando ONP-002, un nuevo neuroesteroide diseñado para tratar lesiones cerebrales traumáticas leves (mTBI) o conmociones a través de la administración intranasal, lo que permite una rápida absorción y una entrega dirigida al cerebro. El summit reunió a líderes de la industria para discutir innovaciones en la entrega intranasal de medicamentos, centrándose en terapias del SNC, tratamientos de uso de emergencia y aplicaciones para enfermedades infecciosas.
Oragenics (NYSE American: OGEN)은 2025년 4월 1일부터 3일까지 보스턴에서 열리는 제3회 비강 제형 및 전달 정상 회담에 참여한다고 발표했습니다. 최고 의료 책임자인 제임스 켈리 박사는 패널 토론에 참여하여 비강 약물 전달 최적화 및 신경학적 치료 접근법에 대한 통찰력을 공유했습니다.
회사는 비강 투여를 통해 경미한 외상성 뇌손상(mTBI) 또는 뇌진탕을 치료하기 위해 설계된 새로운 신경스테로이드 ONP-002를 개발 중이며, 이는 빠른 흡수와 목표 지향적인 뇌 전달을 가능하게 합니다. 이번 정상 회담은 CNS 치료제, 응급 사용 치료 및 감염병 응용에 대한 혁신을 논의하기 위해 업계 리더들을 모았습니다.
Oragenics (NYSE American: OGEN) a annoncé sa participation au 3ème Sommet sur la Formulation et la Livraison Nasale, qui se tiendra du 1er au 3 avril 2025 à Boston. Le directeur médical, Dr. James Kelly, a rejoint une discussion en panel, partageant des idées sur l'optimisation de la délivrance intranasale des médicaments et les approches de traitement neurologique.
L'entreprise développe ONP-002, un nouveau neurostéroïde conçu pour traiter les lésions cérébrales traumatiques légères (mTBI) ou les commotions cérébrales par administration intranasale, ce qui permet une absorption rapide et une livraison ciblée au cerveau. Le sommet a rassemblé des leaders de l'industrie pour discuter des innovations dans la délivrance intranasale des médicaments, en se concentrant sur les thérapeutiques du SNC, les traitements d'urgence et les applications pour les maladies infectieuses.
Oragenics (NYSE American: OGEN) gab seine Teilnahme am 3. Nasalen Formulierungs- und Liefergipfel bekannt, der vom 1. bis 3. April 2025 in Boston stattfinden wird. Der Chief Medical Officer, Dr. James Kelly, nahm an einer Podiumsdiskussion teil und teilte Erkenntnisse zur Optimierung der intranasalen Medikamentenabgabe und zu neurologischen Behandlungsansätzen.
Das Unternehmen entwickelt ONP-002, ein neuartiges Neurosteroid, das zur Behandlung von leichten traumatischen Hirnverletzungen (mTBI) oder Gehirnerschütterungen durch intranasale Verabreichung konzipiert ist, die eine schnelle Absorption und gezielte Abgabe an das Gehirn ermöglicht. Der Gipfel brachte Branchenführer zusammen, um über Innovationen in der intranasalen Medikamentenabgabe zu diskutieren, mit einem Fokus auf CNS-Therapeutika, Notfallbehandlungen und Anwendungen bei Infektionskrankheiten.
- Development of innovative intranasal drug delivery system for brain injury treatment
- Strategic presence at major industry conference demonstrating technological leadership
- None.
SARASOTA, Fla., April 07, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company focused on developing novel intranasal therapies for brain-related disorders, today announced that Chief Medical Officer Dr. James Kelly participated in a panel discussion at the 3rd Nasal Formulation & Delivery Summit, which took place April 1-3, 2025, in Boston, MA.
The conference brought together industry leaders to discuss the latest innovations in intranasal drug delivery, with a focus on CNS therapeutics, emergency-use treatments, and infectious disease applications. Dr. Kelly shared key insights on optimizing intranasal drug delivery, its advantages in neurological treatment, and Oragenics' approach to improving concussion patient outcomes.
Oragenics is advancing ONP-002, a novel neurosteroid designed to treat mild traumatic brain injury (mTBI) aka concussion, leveraging intranasal administration for rapid absorption and targeted brain delivery. The company’s participation in this summit underscores its commitment to innovation in non-invasive CNS therapeutics and sharing insights with the intranasal research community.
For more information about the 3rd Nasal Formulation & Delivery Summit, visit https://www.nasal-formulation-delivery.com/.
Investor Contact
Rich Cockrell
866.889.1972
ogen@cg.capital
About Oragenics, Inc.
Oragenics is a biotechnology company focused on developing intranasal therapeutics for neurological disorders, including its lead candidate, ONP-002, for the treatment of mild traumatic brain injury (mTBI) or concussion. The Company is also advancing proprietary powder formulations and intranasal delivery technology to enhance drug administration. For more information, visit www.oragenics.com.
FAQ
What is Oragenics' (OGEN) main drug candidate for treating concussions?
When and where did Oragenics (OGEN) participate in the Nasal Formulation Summit?
What is the delivery method for Oragenics' (OGEN) concussion treatment?
What therapeutic areas were discussed at the 2025 Nasal Formulation Summit where OGEN presented?
